<DOC>
	<DOC>NCT00964028</DOC>
	<brief_summary>This study will evaluate the safety and reactogenicity of Infanrix-IPV/Hib given as a three-dose primary vaccination course to healthy infants at 2-3-4 or 3-4-5 months of age.</brief_summary>
	<brief_title>Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male or female infant between, and including, 60 and 90 days of age at the time of the first study visit. Born after a gestation period of 36 to 42 weeks inclusive. Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study. Written informed consent obtained from the parent or guardian of the subject. Healthy subjects as established by medical history and clinical examination before entering into the study. Use of any investigational or nonregistered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period. Chronic administration of immunosuppressants or other immunemodifying drugs since birth. Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period. Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period, with the exception of hepatitis B vaccine. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a noninvestigational product. Evidence of previous or intercurrent diphtheria, tetanus, pertussis, poliomyelitis and/or Hib disease. Previous vaccination against diphtheria, tetanus, pertussis, poliovirus and/or Haemophilus influenzae type b diseases. History of seizures or progressive neurological disease. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Major congenital defects or serious chronic illness. The following condition is temporary or selflimiting and a subject may be vaccinated once the condition has resolved and no other exclusion criteria are met: • Current febrile illness or axillary temperature &gt; 37.0 ºC or other moderate to severe illness within 24 hours of study vaccine administration.</criteria>
	<gender>All</gender>
	<minimum_age>60 Days</minimum_age>
	<maximum_age>90 Days</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Combined vaccine</keyword>
</DOC>